Complications of immunotherapy in the course of long-term response in a patient with non-small cell lung cancer

Oncology in Clinical Practice
Online first Complications of immunotherapy in the course of long-term response in a patient with non-small cell lung cancer

Online first

Clinical vignette

Published online: 2024-06-21

Page views 221

Article views/downloads 108

Get Citation

Connect on Social Media

Anita S. Gorzelak-Magiera¹²

, Małgorzata Domagała-Haduch¹²

, Iwona Gisterek-Grocholska²³

DOI: 10.5603/ocp.100043

Not available

Keywords: pembrolizumablung adenocarcinomaimmunotherapy

Mok TSK, Wu YL, Kudaba I, et al. KEYNOTE-042 Investigators. Pembrolizumab versus chemotherapy for previously untreated, PD-L1-expressing, locally advanced or metastatic non-small-cell lung cancer (KEYNOTE-042): a randomised, open-label, controlled, phase 3 trial. Lancet. 2019; 393(10183): 1819–1830.
CrossRefPubMed
Wilky BA. Immune checkpoint inhibitors: The linchpins of modern immunotherapy. Immunol Rev. 2019; 290(1): 6–23.
CrossRefPubMed
Cybulska-Stopa B, Czarnecka AM, Kamińska-Winciorek G, Rutkowski P. Bezpieczeństwo immunoterapii: zasady postępowania profilaktyczno-terapeutycznego w przypadku wystąpienia działań niepożądanych. Wyd. 2. Via Medica, Gdańsk 2022.
Liu H, Li Y, Li J, et al. Musculoskeletal adverse events induced by immune checkpoint inhibitors: a large-scale pharmacovigilance study. Front Pharmacol. 2023; 14: 1199031.
CrossRefPubMed